Published in Obstet Gynecol on March 01, 2010
Carcinosarcoma of the ovary: natural history, patterns of treatment, and outcome. Gynecol Oncol (2013) 1.03
Conservative treatment in early cervical cancer. Int J Biomed Sci (2013) 0.79
Prognostic significance of mucinous differentiation of endometrioid adenocarcinoma of the endometrium. Cancer Invest (2013) 0.79
Conservative Treatment of Stage IA1 Adenocarcinoma of the Uterine Cervix during Pregnancy: Case Report and Review of the Literature. Case Rep Obstet Gynecol (2014) 0.78
Fertility Preservation: A Key Survivorship Issue for Young Women with Cancer. Front Oncol (2016) 0.78
Fertility preservation in women with cervical, endometrial or ovarian cancers. Gynecol Oncol Res Pract (2016) 0.78
Primary cervical carcinoma cell lines overexpress epithelial cell adhesion molecule (EpCAM) and are highly sensitive to immunotherapy with MT201, a fully human monoclonal anti-EpCAM antibody. Int J Gynecol Cancer (2010) 0.76
Analysis of treatment modalities and prognosis on microinvasive cervical cancer: a 10-year cohort study in China. J Gynecol Oncol (2014) 0.75
Conservative treatment of coexisting microinvasive squamous and adenocarcinoma of the cervix: report of two cases and literature review. Onco Targets Ther (2016) 0.75
Conservative Surgery for Early Cervical Cancer. Indian J Surg Oncol (2015) 0.75
Fertility-preserving surgery in patients with early stage cervical carcinoma. ISRN Oncol (2012) 0.75
Robotically assisted vs laparoscopic hysterectomy among women with benign gynecologic disease. JAMA (2013) 4.67
Perioperative comparative effectiveness of anesthetic technique in orthopedic patients. Anesthesiology (2013) 3.45
Trabectedin plus pegylated liposomal Doxorubicin in recurrent ovarian cancer. J Clin Oncol (2010) 3.33
Comparative effectiveness of robotic versus laparoscopic hysterectomy for endometrial cancer. J Clin Oncol (2012) 2.59
Resource utilization for ovarian cancer patients at the end of life: how much is too much? Gynecol Oncol (2005) 2.26
Latest research and treatment of advanced-stage epithelial ovarian cancer. Nat Rev Clin Oncol (2013) 2.24
Trends in relative survival for ovarian cancer from 1975 to 2011. Obstet Gynecol (2015) 2.22
Society of Gynecologic Oncologists Education Committee statement on risk assessment for inherited gynecologic cancer predispositions. Gynecol Oncol (2007) 2.20
Lymphadenectomy influences the utilization of adjuvant radiation treatment for endometrial cancer. Am J Obstet Gynecol (2011) 2.19
Racial disparities for uterine corpus tumors: changes in clinical characteristics and treatment over time. Cancer (2009) 2.15
Surgical-pathological predictors of disease-free survival and risk groupings for IB2 cervical cancer: do the traditional models still apply? Gynecol Oncol (2004) 2.08
Nationwide trends in the performance of inpatient hysterectomy in the United States. Obstet Gynecol (2013) 2.05
Prognostic significance of adenocarcinoma histology in women with cervical cancer. Gynecol Oncol (2012) 1.98
Comparative performance of the 2009 international Federation of gynecology and obstetrics' staging system for uterine corpus cancer. Obstet Gynecol (2010) 1.98
Prophylactic and risk-reducing bilateral salpingo-oophorectomy: recommendations based on risk of ovarian cancer. Obstet Gynecol (2010) 1.94
Predictors of massive blood loss in women with placenta accreta. Am J Obstet Gynecol (2011) 1.86
Prevalence of defective DNA mismatch repair and MSH6 mutation in an unselected series of endometrial cancers. Proc Natl Acad Sci U S A (2003) 1.83
Primary therapy for early-stage cervical cancer: radical hysterectomy vs radiation. Am J Obstet Gynecol (2009) 1.75
Trends in hospital volume and patterns of referral for women with gynecologic cancers. Obstet Gynecol (2013) 1.72
Use of complementary and alternative medicine among women with gynecologic cancers. Gynecol Oncol (2002) 1.72
The impact of sleep apnea on postoperative utilization of resources and adverse outcomes. Anesth Analg (2014) 1.69
Cervical carcinoma in the elderly: an analysis of patterns of care and outcome. Cancer (2005) 1.68
Defining the limits of radical cytoreductive surgery for ovarian cancer. Gynecol Oncol (2011) 1.66
Management of symptomatic ascites in recurrent ovarian cancer patients using an intra-abdominal semi-permanent catheter. Am J Hosp Palliat Care (2002) 1.65
Sleep apnea and total joint arthroplasty under various types of anesthesia: a population-based study of perioperative outcomes. Reg Anesth Pain Med (2013) 1.62
Effect of surgical volume on outcomes for laparoscopic hysterectomy for benign indications. Obstet Gynecol (2012) 1.58
Penetrance and expressivity of MSH6 germline mutations in seven kindreds not ascertained by family history. Am J Hum Genet (2004) 1.57
Regionalization of care for obstetric hemorrhage and its effect on maternal mortality. Obstet Gynecol (2010) 1.56
The effect of surgeon volume on outcomes and resource use for vaginal hysterectomy. Obstet Gynecol (2010) 1.56
Scientific evidence underlying the American College of Obstetricians and Gynecologists' practice bulletins. Obstet Gynecol (2011) 1.55
Trends in surgical mesh use for pelvic organ prolapse from 2000 to 2010. Obstet Gynecol (2012) 1.55
Ventilator-associated pneumonia: current status and future recommendations. J Clin Monit Comput (2010) 1.54
A prospective study evaluating the clinical relevance of a chemoresponse assay for treatment of patients with persistent or recurrent ovarian cancer. Gynecol Oncol (2013) 1.54
Contemporary management of endometrial cancer. Lancet (2012) 1.51
Variation in ovarian conservation in women undergoing hysterectomy for benign indications. Obstet Gynecol (2013) 1.46
Utilization of critical care services among patients undergoing total hip and knee arthroplasty: epidemiology and risk factors. Anesthesiology (2012) 1.41
Postpartum sterilization: small incision, big complication. Obstet Gynecol (2008) 1.40
Detection of endobronchial intubation by monitoring the CO2 level above the endotracheal cuff. J Clin Monit Comput (2014) 1.39
Lack of benefit of concurrent chemotherapy in patients with cervical cancer and negative lymph nodes by FDG-PET. Int J Radiat Oncol Biol Phys (2005) 1.39
Utility of parametrectomy for early stage cervical cancer treated with radical hysterectomy. Cancer (2007) 1.38
Frequent HOXA11 and THBS2 promoter methylation, and a methylator phenotype in endometrial adenocarcinoma. Clin Cancer Res (2003) 1.36
SGO White Paper on ovarian cancer: etiology, screening and surveillance. Gynecol Oncol (2010) 1.27
Comparative perioperative outcomes associated with neuraxial versus general anesthesia for simultaneous bilateral total knee arthroplasty. Reg Anesth Pain Med (2012) 1.25
Fertility preservation in young women with epithelial ovarian cancer. Cancer (2009) 1.24
Quality of perioperative venous thromboembolism prophylaxis in gynecologic surgery. Obstet Gynecol (2011) 1.21
Preoperative lymph node staging of early-stage cervical carcinoma by [18F]-fluoro-2-deoxy-D-glucose-positron emission tomography. Cancer (2005) 1.20
The utility of preoperative endometrial sampling for the detection of uterine sarcomas. Gynecol Oncol (2008) 1.17
Natural history and outcome of mucinous carcinoma of the ovary. Am J Obstet Gynecol (2011) 1.16
Prospective evaluation of FDG-PET for detecting pelvic and para-aortic lymph node metastasis in uterine corpus cancer. Gynecol Oncol (2004) 1.15
Effect of surgical volume on morbidity and mortality of abdominal hysterectomy for endometrial cancer. Obstet Gynecol (2011) 1.14
Failure to rescue as a source of variation in hospital mortality for ovarian cancer. J Clin Oncol (2012) 1.14